NCT05389709View on ClinicalTrials.gov

A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting

CompletedOBSERVATIONAL
Enrollment

184

Participants

Timeline

Start Date

June 4, 2022

Primary Completion Date

May 11, 2023

Study Completion Date

May 11, 2023

Conditions
Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional DyspepsiaIrritable Bowel SyndromeFunctional Dyspepsia
Interventions
DRUG

Iberogast (STW5-II, BAY98-7410)

Survey without any intervention assigned in the study.

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05389709 - A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting | Biotech Hunter | Biotech Hunter